Literature DB >> 2926718

Radioactive iodine treatment of a functional thyroid carcinoma producing hyperthyroidism in a dog.

M E Peterson1, P P Kintzer, J R Hurley, D V Becker.   

Abstract

Radioactive iodine (131I) was used in the treatment of a 12-year-old female dog with hyperthyroidism resulting from a large, unresectable (and metastatic) thyroid carcinoma associated with signs of severe inspiratory stridor and dyspnea. Hyperthyroidism was diagnosed on the basis of clinical signs (polyuria, polydipsia, polyphagia, weight loss, nervousness) and high basal serum thyroxine (T4) concentrations, as well as thyroid radioiodine kinetic studies that showed a high radioiodine uptake into the thyroid (% thyroid uptake) and markedly increased serum concentrations of protein-bound iodine-131 (PB131I) after 131I tracer injection. Thyroid imaging revealed diffuse radionuclide accumulation by the tumor, which involved both thyroid lobes. The dog was treated with three large doses of radioiodine (131I), ranging from 60 to 75 mCi, given at intervals of 5 to 7 months. The dog became euthyroid, and the size of the tumor decreased by approximately 25% after each 131I treatment, improving the severe inspiratory stridor and dyspnea, but both the hyperthyroid state and breathing difficulty recurred within a few months of each treatment. The dog was euthanatized 5 months after the last treatment because of progressive tracheal compression and pulmonary metastasis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2926718     DOI: 10.1111/j.1939-1676.1989.tb00324.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  1 in total

1.  Planar and single-photon emission computed tomography imaging in dogs with thyroid tumors: 68 cases.

Authors:  Marit F van den Berg; Sylvie Daminet; Emmelie Stock; Eva Vandermeulen; Stephanie Scheemaeker; Miguel Campos; Hans S Kooistra; Sara Galac; Luc Duchateau; Kathelijne Peremans
Journal:  J Vet Intern Med       Date:  2020-09-26       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.